Targovax - Småprat 2 (TRVX) 1

[TekBot]

Reminder: Invitation to Targovax’s Capital Markets Day 18 February 2021

Oslo, 18 February 2021 - Targovax ASA, a clinical stage immuno-oncology company
developing immune activators to target hard-to-treat solid tumors, will host a
virtual Capital Markets Day for investors, analysts and journalists today at
…

Vis børsmeldingen

2:30 PM CET. The Capital Markets Day will feature presentations from executive
management and Alexander Shousthari, Clinical Director Melanoma Services at
Memorial Sloan Kettering Cancer Center, and will be webcast live and accessible
at Capital markets day 2021 – Targovax

Based on the strong clinical data that are now generated on ONCOS-102, Targovax
has a solid fundament to move into late stage clinical development. We also have
a broader pipeline of preclinical assets that could create a broader horizon of
opportunities in the future. The Capital Markets day will feature presentations
updating the market on these aspects.

The agenda will be as follows:

                              Agenda &
                              speakers

2:30 Welcome Øystein Soug, CEO, Targovax
-2:40 PM
2:40 Anti-PD1 refractory melanoma Alexander N. Shoushtari, MD
-3:25 PM
3:25 ONCOS-102 development program Magnus Jäderberg, MD, CMO, Targovax
-3:45 PM
5-minute
break
3:50 Immune activation Victor Levitsky, PhD CSO, Targovax
-4:05 PM
4:05 Preclinical pipeline update Victor Levitsky, PhD, CSO, Targovax
-4:15 PM
4:15 4Q update Torbjørn Furuseth, MD, CFO, Targovax
-4:25 PM
4:25 PM Closing remarks Øystein Soug, CEO, Targovax

The presentations will be made available on the company´s website after
The presentations will be made available on the company´s website after the end
of the meeting. Questions can be submitted through the webcast throughout the
event.

Biography:

Dr. Alexander Shoushtari is a renowned expert in melanoma, with a research focus
on checkpoint refractory melanomas. He is a Clinical Director and Assistant
attending physician at Melanoma Services, Dept of Medicine, Memorial Sloan
Kettering Cancer Center. Dr. Alexander Shoushtari is Principal investigator of
several immunotherapy trials, including the ONCOS-102 phase I trial in CPI
refractory advanced melanoma.

---

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777

About Targovax

Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients with targeted
therapeutic cancer immunotherapies. Targovax’s pipeline aims at different cancer
indications, including melanoma, mesothelioma and colorectal cancer. The
products are designed to harness the patient’s own immune system to fight the
cancer, whilst also delivering a favorable safety and tolerability profile.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging data in several indications, in monotherapy and in multiple
combination, the next development steps for ONCOS-102 will involve a clinical
trial with registration intent in checkpoint inhibitor refractory melanoma.

Kilde

[Helt1]

Eller partner

[RubenAyala]

Stellar data og ingen klingende mynt på bordet up front ? Klinger rart i mine ører

[Longtrader]

Ja, får håpe de drar på litt snart:)

[Moborg]

Null inntekter – halverte utgiftene

[BioMed]

Targovax fikk et driftsresultat på minus 23 millioner kroner i fjerde kvartal 2020, mot et driftsresultat på minus 39 millioner kroner i samme periode året før

[Josseball]

DNB opprettholder kjøpsanbefaling og holder fast på kursmålet på 17,- kr

Edit: og det er før oppdateringer fra CMD i dag.

AD210218.pdf

[Longtrader]

17kr er en fin start , så håper vi de snart oppjusterer​:rocket:

[Bilballs]

Når starter CMD idag? Har sjæmpen på kjøl. Tror noe kommer ut av hatten

[dri]

Halv tre

[RubenAyala]

Det kan vel ikke komme noe sprengstoff underveis uten halt ? Etter close derimot ?

[solvoll]

Siden det virker som om det er først og fremst melanom de vil gå videre med, så blir det spennende å se hvordan meso blir tatt videre.

Vi vet at Merck er interessert i meso siden de allerede er partner der med spons og rådgivning.
Spørsmålet er om de er interessert i å betale for å kjøre hele selv🙃

[Frs2904]

Da kan vi snart forvente en melding om fast track i melanom

[Aagaard]

Det er mit klare indtryk, at der er stor nervøsitet omkring CMD præsentationen senere i dag. Soug’s ordvalg tror jeg kan trække kursen markant i begge retninger🤞

[Whatsthat]

@Josseball

DNB opprettholder kjøpsanbefaling og holder fast på kursmålet på 17,- kr

De kom vel ikke med noen ny oppdatert analyse på 17 kr idag?

[Domboshawa]

Jeg føler også at dette er litt være eller ikke være hvis de ikke kommer opp med noe konkret rundt et samarbeid som tar selskapet videre. De har som tidligere formidlet samtaler med BP - da er det vel gitt at “best in class” må generere noe.
Tror de fleste aksjonærene begynner å bli slitne og trenger en form for progresjon her.

[BioMed]

We are also entering 2021 with a broader pipeline of preclinical assets that could create a broader
set of opportunities in the future. 2021 could also mark the revival of the mutant RAS platform
with IOVaxis potentially exercises the license option.
We enter 2021 with optimism and look forward to providing further updates on our clinical
progress.

[Xon]

Mer enn 30% opp siste året og Fast-Track for 3 dager siden. Blir ikke særlig sliten av det.

[Josseball]

Nei, den er gammel. Ble bare nevnt i rapporten for aksjemarkedet i dag. Men det kan jo hende de lager ny analyse hvis det kommer noe nyheter i dag sol gir grunnlag for å oppdatere analysen​:crossed_fingers:t2:

[Celestar]

Tydligvis ikke vært aksjonær her så lenge du isåfall…